295 related articles for article (PubMed ID: 23577210)
1. Evaluation of (89)Zr-labeled human anti-CD147 monoclonal antibody as a positron emission tomography probe in a mouse model of pancreatic cancer.
Sugyo A; Tsuji AB; Sudo H; Nagatsu K; Koizumi M; Ukai Y; Kurosawa G; Zhang MR; Kurosawa Y; Saga T
PLoS One; 2013; 8(4):e61230. PubMed ID: 23577210
[TBL] [Abstract][Full Text] [Related]
2. Preclinical evaluation of ⁸⁹Zr-labeled human antitransferrin receptor monoclonal antibody as a PET probe using a pancreatic cancer mouse model.
Sugyo A; Tsuji AB; Sudo H; Nagatsu K; Koizumi M; Ukai Y; Kurosawa G; Zhang MR; Kurosawa Y; Saga T
Nucl Med Commun; 2015 Mar; 36(3):286-94. PubMed ID: 25460304
[TBL] [Abstract][Full Text] [Related]
3. ImmunoPET Imaging of Insulin-Like Growth Factor 1 Receptor in a Subcutaneous Mouse Model of Pancreatic Cancer.
England CG; Kamkaew A; Im HJ; Valdovinos HF; Sun H; Hernandez R; Cho SY; Dunphy EJ; Lee DS; Barnhart TE; Cai W
Mol Pharm; 2016 Jun; 13(6):1958-66. PubMed ID: 27054683
[TBL] [Abstract][Full Text] [Related]
4. ImmunoPET of trophoblast cell-surface antigen 2 (Trop-2) expression in pancreatic cancer.
Chen W; Li M; Younis MH; Barnhart TE; Jiang D; Sun T; Lang JM; Engle JW; Zhou M; Cai W
Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):861-870. PubMed ID: 34519889
[TBL] [Abstract][Full Text] [Related]
5. Zirconium-89 labeled panitumumab: a potential immuno-PET probe for HER1-expressing carcinomas.
Bhattacharyya S; Kurdziel K; Wei L; Riffle L; Kaur G; Hill GC; Jacobs PM; Tatum JL; Doroshow JH; Kalen JD
Nucl Med Biol; 2013 May; 40(4):451-7. PubMed ID: 23454247
[TBL] [Abstract][Full Text] [Related]
6. ImmunoPET imaging of tissue factor expression in pancreatic cancer with
Hernandez R; England CG; Yang Y; Valdovinos HF; Liu B; Wong HC; Barnhart TE; Cai W
J Control Release; 2017 Oct; 264():160-168. PubMed ID: 28843831
[TBL] [Abstract][Full Text] [Related]
7. Dual combination therapy targeting DR5 and EMMPRIN in pancreatic adenocarcinoma.
Kim H; Zhai G; Samuel SL; Rigell CJ; Umphrey HR; Rana S; Stockard CR; Fineberg NS; Zinn KR
Mol Cancer Ther; 2012 Feb; 11(2):405-15. PubMed ID: 22203731
[TBL] [Abstract][Full Text] [Related]
8. ImmunoPET Imaging of Pancreatic Tumors with
Sobol NB; Korsen JA; Younes A; Edwards KJ; Lewis JS
Mol Imaging Biol; 2021 Feb; 23(1):84-94. PubMed ID: 32909244
[TBL] [Abstract][Full Text] [Related]
9. Immuno-PET and Targeted α-Therapy Using Anti-Glypican-1 Antibody Labeled with
Watabe T; Kabayama K; Naka S; Yamamoto R; Kaneda K; Serada S; Ooe K; Toyoshima A; Wang Y; Haba H; Kurimoto K; Kobayashi T; Shimosegawa E; Tomiyama N; Fukase K; Naka T
J Nucl Med; 2023 Dec; 64(12):1949-1955. PubMed ID: 37827841
[TBL] [Abstract][Full Text] [Related]
10. ImmunoPET/NIRF/Cerenkov multimodality imaging of ICAM-1 in pancreatic ductal adenocarcinoma.
Li M; Wei W; Barnhart TE; Jiang D; Cao T; Fan K; Engle JW; Liu J; Chen W; Cai W
Eur J Nucl Med Mol Imaging; 2021 Aug; 48(9):2737-2748. PubMed ID: 33537836
[TBL] [Abstract][Full Text] [Related]
11. ImmunoPET imaging of renal cell carcinoma with (124)I- and (89)Zr-labeled anti-CAIX monoclonal antibody cG250 in mice.
Stillebroer AB; Franssen GM; Mulders PF; Oyen WJ; van Dongen GA; Laverman P; Oosterwijk E; Boerman OC
Cancer Biother Radiopharm; 2013 Sep; 28(7):510-5. PubMed ID: 23697926
[TBL] [Abstract][Full Text] [Related]
12.
Price EW; Carnazza KE; Carlin SD; Cho A; Edwards KJ; Sevak KK; Glaser JM; de Stanchina E; Janjigian YY; Lewis JS
J Nucl Med; 2017 Sep; 58(9):1386-1394. PubMed ID: 28280216
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Next-Generation Anti-CD20 Antibodies Labeled with
Yoon JT; Longtine MS; Marquez-Nostra BV; Wahl RL
J Nucl Med; 2018 Aug; 59(8):1219-1224. PubMed ID: 29348316
[TBL] [Abstract][Full Text] [Related]
14. ImmunoPET Predicts Response to Met-targeted Radioligand Therapy in Models of Pancreatic Cancer Resistant to Met Kinase Inhibitors.
Escorcia FE; Houghton JL; Abdel-Atti D; Pereira PR; Cho A; Gutsche NT; Baidoo KE; Lewis JS
Theranostics; 2020; 10(1):151-165. PubMed ID: 31903112
[No Abstract] [Full Text] [Related]
15. Immuno-PET of the hepatocyte growth factor receptor Met using the 1-armed antibody onartuzumab.
Jagoda EM; Lang L; Bhadrasetty V; Histed S; Williams M; Kramer-Marek G; Mena E; Rosenblum L; Marik J; Tinianow JN; Merchant M; Szajek L; Paik C; Cecchi F; Raffensperger K; Jose-Dizon JM; Bottaro DP; Choyke P
J Nucl Med; 2012 Oct; 53(10):1592-600. PubMed ID: 22917884
[TBL] [Abstract][Full Text] [Related]
16.
Poty S; Mandleywala K; O'Neill E; Knight JC; Cornelissen B; Lewis JS
Theranostics; 2020; 10(13):5802-5814. PubMed ID: 32483420
[No Abstract] [Full Text] [Related]
17.
Fung K; Vivier D; Keinänen O; Sarbisheh EK; Price EW; Zeglis BM
Molecules; 2020 May; 25(10):. PubMed ID: 32429033
[TBL] [Abstract][Full Text] [Related]
18. Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30.
Perk LR; Stigter-van Walsum M; Visser GW; Kloet RW; Vosjan MJ; Leemans CR; Giaccone G; Albano R; Comoglio PM; van Dongen GA
Eur J Nucl Med Mol Imaging; 2008 Oct; 35(10):1857-67. PubMed ID: 18491091
[TBL] [Abstract][Full Text] [Related]
19. MicroPET/CT imaging of patient-derived pancreatic cancer xenografts implanted subcutaneously or orthotopically in NOD-scid mice using (64)Cu-NOTA-panitumumab F(ab')2 fragments.
Boyle AJ; Cao PJ; Hedley DW; Sidhu SS; Winnik MA; Reilly RM
Nucl Med Biol; 2015 Feb; 42(2):71-7. PubMed ID: 25456837
[TBL] [Abstract][Full Text] [Related]
20. Immuno-PET Imaging of CD30-Positive Lymphoma Using 89Zr-Desferrioxamine-Labeled CD30-Specific AC-10 Antibody.
Rylova SN; Del Pozzo L; Klingeberg C; Tönnesmann R; Illert AL; Meyer PT; Maecke HR; Holland JP
J Nucl Med; 2016 Jan; 57(1):96-102. PubMed ID: 26514172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]